Vitro Diagnostics Inc. (fka VODG)

[Potse]

Shuster...interesting statements on MSC-Gro Media......

Neuromics CEO Pete Shuster (VODG Director and primary distributor) made some interesting statements today in one of his stem cell discussion groups on LinkedIn (see below).

Apparently a large Australian company involved in stem cell expansion is (or will be) performing tests on VODG's MSC-Gro Media. I gather from Shuster's comments that the Melbourne-based company is (or will be) doing a cost/performance analysis of the VODG product versus the fetal bovine serum-based product the company currently uses.

Also, in light of today's comments by Shuster, it might be worth going back and recalling some statements VODG made in its August 12 press release. I'm not sure if those press release statements are directly related to the activity/discussions that VODG/Neuromics are having with this Australian company, or if they are completely/partially unconnected, but nonetheless it appears that VODG is experiencing or certainly expecting to see significantly increased interest in its media product(s).

From the August 12 press release.....

Our MSC-Gro(tm) Media for cell culture of MSCs and other primary cell lines has numerous competitive advantages including increased cellular recovery and potency when compared to other leading suppliers. We are leveraging this position to attain full regulatory compliance and increased manufacturing capacity for use of this media in the expansion of patient-specific MSCs for clinical applications. Human MSC transplantation is gaining positive results from numerous studies of efficacy & safety especially in the treatment of osteoarthritis, a common condition that often leads to joint replacement. We are in discussions with various third parties representing significant commercial opportunities for us to also recognize increased revenue through this initiative.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105414535

Below are some snippets of Pete Shuster's posts today, and I've placed in bold the most noteworthy parts of Shuster's statements......

1)

Thank you Henry. I wonder how much these "fleecers" are impacting the FDA? There seems to be a lot of press on these clinics. The focus on these are misplaced. I would like to see more educating of patients. This would include how to chose the best treatment and clinic. For example, Neuromics and Vitro Biopharma are working with a large processor, outside the US, to optimize their purifying and expanding of ADMSCs. They serve a growing population of Stem Cell Transplant clinics. Each lot of expanded cells are tested to make sure they comply with published International Standards. These standards include expression of expanded cells for CD Markers 90,73 and 105 be >90%. Countries that allow expansion are already ahead of the US. In fact, these countries are enjoying economic windfalls from Medical Tourism. My advise to patients is to do their homework and make sure their cells are being expanded in facilities that comply with all international regulations and standards. I would also suggest they request proof that clinics and processors are in 100% compliance with international regs and standards.

2)

With all due respect, Dr. Noll, again, you misinterepret my postings. We are being engaged with a company that is already expanding ADMCS with FBS/a-MEM. They are piloting our defined MSCGro media: (www.neuromics.com/ittrium/visit/A1x66x1y1x85b1x1x9cy1x622ex1x96y1xa711x1x82) to see if it would be better and more cost effective. The company is in Melbourne, Australia and they are highly regulated. Our value add to them is providing MEDIA ONLY. Further, given the FDA regs, there are no opportunities to sell the media in the U.S. for commercial use.

https://www.linkedin.com/groups/What-are-Patients-Saying-4117443.S.5963391313628979200?trk=groups_search_item_list-0-b-cmr